PRQR

ProQR Therapeutics N.V. Ordinary Shares

1.31

USD

-0.07

-5.07%

Nov 10, 15:59 UTC -5

Closed

After-Market

1.35

+0.04

+3.21%

ProQR Therapeutics N.V. Ordinary Shares (PRQR) Earnings

PRQR Earnings Reports

Positive Surprise Ratio

PRQR beat 30 of 42 last estimates.

71%

Next Report

Date of Next Report

Mar 10, 2027

Estimate for Q4 26 (Revenue/ EPS)

$4.29M

-$0.11

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

-8.48%

+37.50%

ProQR Therapeutics N.V. Ordinary Shares earnings per share and revenue

On Nov 05, 2026, PRQR reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.10 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 4.51 million, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.11 USD, with revenue projected to reach 4.29 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were ProQR Therapeutics N.V. Ordinary Shares's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, ProQR Therapeutics N.V. Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to ProQR Therapeutics N.V. Ordinary Shares's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is ProQR Therapeutics N.V. Ordinary Shares expected to report next?

The next earning report is scheduled for Mar 10, 2027.

What are the forecasts for ProQR Therapeutics N.V. Ordinary Shares's next earnings report?

Based on -- analysts, ProQR Therapeutics N.V. Ordinary Shares is expected to report EPS of -$0.11 and revenue of $4.29M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.